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Dysregulation of the cell cycle characterizes many
cancer subtypes, providing a rationale for devel-
oping cyclin-dependent kinase (CDK) inhibitors.
Potent CDK2 inhibitors might target certain cancers
in which CCNE1 is amplified. However, current
CDK2 inhibitors also inhibit CDK1, generating a
toxicity liability. We have used biophysical measure-
ments and X-ray crystallography to investigate the
ATP-competitive inhibitor binding properties of cy-
clin-free and cyclin-bound CDK1 and CDK2. We
show that these kinases can readily be distinguished
by such inhibitors when cyclin-free, but not when cy-
clin-bound. The basis for this discrimination is un-
clear from either inspection or molecular dynamics
simulation of ligand-bound CDKs, but is reflected in
the contacts made between the kinase N- and
C-lobes. We conclude that there is a subtle but pro-
found difference between the conformational energy
landscapes of cyclin-free CDK1 and CDK2. The un-
usual properties of CDK1 might be exploited to
differentiate CDK1 from other CDKs in future cancer
therapeutic design.
INTRODUCTION
Members of the cyclin-dependent protein kinase (CDK) family
have diverse cellular roles that include regulation of the cell cycle
and transcription and, in certain cell types, differentiation (Lim
and Kaldis, 2013; Malumbres, 2014; Morgan, 2007). Dysregula-
tion of CDK activity is frequently associated with inappropriate
cell-cycle progression and, as a result, various members of the
family have been pursued as targets for anti-cancer drug design
(Kim et al., 2013; Toogood et al., 2005; Whittaker et al., 2017).
CCNE1 encodes cyclin E, which binds to CDK2 to drive cells
through the G1/S cell-cycle transition (Koff et al., 1991; Malum-
bres, 2014; Morgan, 2007). The results observed when CDK2
levels are genetically suppressed indicate that its function isCell Chemical Biology 26, 1–10, J
This is an open access article undnot essential for mitosis in normal tissue development and ho-
meostasis (Berthet et al., 2003). In contrast, tumor cells in which
CCNE1 is amplified are critically dependent on CDK2 and cyclin
E for survival (Etemadmoghadam et al., 2013a, 2013b). CCNE1
amplification or cyclin E1 overexpression has also been
described in a number of other cancers including osteosarcoma
(Lockwood et al., 2011), breast (Karakas et al., 2016), and non-
small-cell lung cancer (Freemantle and Dmitrovsky, 2010).
Such ‘‘oncogene-addiction’’ to cyclin E occurs in a significant
cohort of high-grade serous ovarian cancer (HGSOC) patients
and confers a particularly poor outcome to current therapy (Kan-
ska et al., 2016; Kroeger and Drapkin, 2017; Patch et al., 2015).
These findings suggest that a CDK2-selective inhibitor could be
clinically beneficial in these cancer subtypes.
CDKs share a conserved protein kinase domain that com-
prises a smaller N-terminal lobe linked through a hinge to a larger
C-terminal fold (Endicott et al., 2012). Cyclin-free CDKs are inac-
tive because the C helix, the activation segment (the sequence
between the conserved DFG and APEmotifs, single-letter amino
acid code, CDK1 residues 146–173), and the P loop (the glycine-
rich phosphate binding sequence, CDK1 residues 11–17) are
inappropriately disposed to promote catalysis (De Bondt et al.,
1993; Russo et al., 1996). The C helix, which lies at the back of
the active site cleft, is rotated out of the fold, its position dictated
in part by the DFG sequence adopting a short a-helical structure.
The activation segment is flexible, illustrated in a number of cy-
clin-free structures determined by X-ray crystallography, where
it is either not visible or adopts alternative structures that fold to-
ward the P loop (Brown et al., 2015; Martin et al., 2017).
All CDKs require binding to a cognate cyclin partner to re-
mould the kinase fold from an inactive conformation to one
capable of phospho-transfer. For example, CDK1 and CDK2
are partnered by cyclins A and B, and A and E, respectively (Ma-
lumbres, 2014). Cyclins bind to the C helix, and remodel the
CDKs so that residues of the C helix and the DFG motif are
aligned for catalysis (Echalier et al., 2010; Morgan, 2007). Cyclin
binding also restructures the activation segment and, generally,
this re-organization is accompanied by phosphorylation of the
activation segment by the CDK-activating kinase (Desai et al.,
1995; Merrick et al., 2008). These structural changes, local
to the active site, reflect a global change in the relative posi-
tions of the kinase N- and C-lobes. However, structural studiesanuary 17, 2019 ª 2018 The Authors. Published by Elsevier Ltd. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
A B Figure 1. ATP-Competitive Inhibitor Binding
to the CDK Active Site
(A) Active site sequence conservation between
CDK1 and CDK2. The CDK2 structure bound to ATP
is drawn (PDB: 1HCK). Residues within 4.5 A˚ of ATP
are drawn in ball and stick mode in green and are
identical between CDK1 and CDK2. The molecular
surface of the bound ATP is rendered as a trans-
parent blue surface to indicate the volume occupied
within the active site.
(B) CDK inhibitors Alvocidib, AZD5438, CGP74514A,
Dinaciclib, and SU9516 used in this study. The
pharmacophore scaffolds are highlighted in red.
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the catalytically competent Michaelis complex only form upon
binding of both ATP and peptide substrates.
The first generation of non-selective CDK inhibitors that were
evaluated in the clinic showed limited therapeutic benefit due
to dose-limiting toxicities (Whittaker et al., 2017). The essential
role of CDK1 in the normal cell cycle suggests that some of these
toxicities might be avoided by excluding CDK1 from the inhibi-
tory profile of drugs that target CDKs, raising the question of
how CDK1 discrimination might be achieved. Structures of
CDK-cyclin complexes bound to ATP-competitive inhibitors
reveal how differences in amino acid composition and in the
conformation and malleability of sequences in and around the
active site can identify potent and selective molecules (Martin
et al., 2017; Whittaker et al., 2017). More dispersed changes
that reflect the plasticity of the ATP binding site have also been
hypothesized to generate inter-CDK selectivity (Coxon et al.,
2017; Hole et al., 2013; Shao et al., 2013). However, the residues
that contact ATP in a CDK2-cyclin A-AMPPNP-peptide complex
are identical in CDK1 (Brown et al., 1999), while cell-active CDK2
inhibitor series appear not to be sufficiently selective to exert
CCNE1 amplicon-dependent cell growth inhibition in models of
HGSOC (Au-Yeung et al., 2017).
An alternative route to discriminate between CDK2 and CDK1
would be to target the cyclin-free structures of the enzymes. The
structure of CDK1 appears to differ from that of CDK2 in terms of
the disposition of N- and C-terminal lobes, while it also appears
more mobile and malleable (Brown et al., 2015). Inhibitors have
been reported that exploit the conformational flexibility of cy-
clin-free CDK2 to target pockets that stabilize conformations
incompatible with cyclin association (Alexander et al., 2015;
Betzi et al., 2011; Deng et al., 2014). Taken together, these ob-
servations suggest that targeting cyclin-free CDK structures
might provide a selectivity window between closely related
CDK family members.
We have applied a range of biophysical techniques to discover
that ATP-competitive inhibitors bind with a surprisingly low affin-
ity to cyclin-free CDK1 as compared with CDK2. Binding of
CDK1 and CDK2 to their respective cognate partners, cyclin
B and cyclin A, largely removes this difference, so that the
cyclin-bound forms sharemuchmore similar inhibitor binding af-
finities. We conclude that cyclin-free CDK1 binds inhibitors
weakly because its conformational energy landscape offers sta-
ble states that are incompetent to bind inhibitors, thereby
moderating the free energy of binding that derives from pro-2 Cell Chemical Biology 26, 1–10, January 17, 2019tein-ligand interactions. Our results demonstrate that small-
molecule inhibitors that probe the ATP binding site can distin-
guish cyclin-free CDK1 and CDK2, thereby offering a structural
mechanism to enable development of potent and selective
CDK2 inhibitors.
RESULTS
ATP-Competitive Inhibitors Discriminate between
Cyclin-free CDK1 and CDK2
Avoiding the inhibition of CDK1 in a multi-CDK or single-CDK in-
hibition strategy is complicated by the high degree of active site
sequence identity within the CDK family, illustrated for CDKs
1 and 2 in Figure 1A (Figure S1). To explore the potential for
ATP-competitive inhibitors to discriminate between CDK1 and
CDK2, five ATP-competitive CDK inhibitors (Figure 1B) were
selected on the basis of their diverse pharmacophores and sub-
micromolar half maximal inhibitory concentration (IC50) values
toward CDK2-cyclin A and CDK1-cyclin B (Table S1). The set
includes Dinaciclib (Parry et al., 2010), AZD5438 (Byth et al.,
2009), Alvocidib (Flavopiridol) (Carlson et al., 1996), SU9516
(Lane et al., 2001), and CGP74514A (Imbach et al., 1999). To
confirm previously reported activities, these inhibitors were first
tested for their ability to bind to CDK1-cyclin B and CDK2-cyclin
A using isothermal titration calorimetry (ITC) (Tables 1 and S2).
The inhibitor binding isotherms correlate with the reported
IC50 data and our independent IC50 measurements (Table S1).
AZD5438 (Figure 2A), Dinaciclib (Figure S2A), and SU9516 (Fig-
ure S2B) bind with low-nanomolar affinity toward CDK2-cyclin
A and show up to 16-fold selectivity for CDK2-cyclin A over
CDK1-cyclin B (Table 1). Reflecting its pan-CDK inhibition pro-
file, Alvocidib is equipotent toward CDK1-cyclin B and CDK2-
cyclin A (Figure S2C; Table 1). The purine-based CDK1-cyclin
B-selective inhibitor CGP74514A is a less-potent CDK inhibitor
(Table S1), and binds with reduced affinity to CDK1-cyclin B and
to CDK2-cyclin A under these experimental conditions (Fig-
ure S2D; Table 1). Taken together these results show that the
affinities and potencies of a set of structurally diverse ATP-
competitive CDK inhibitors toward CDK2-cyclin A correlate
with their values toward CDK1-cyclin B.
We next investigated the ability of each inhibitor to bind to cy-
clin-free phosphorylated CDK1 and CDK2. A range of inhibitor
binding isotherms were measured for CDK1 (Table 1). Dinaciclib
proved to be the tightest binding inhibitor, with a measured Kd of
0.96 mM (Figure S2A), while the binding of SU9516 did not reach
Table 1. Inhibitor Binding to CDK1-Cyclin B, CDK2-Cyclin A,
CDK1, and CDK2
ITC Kd (nM)
CDK1B CDK2A CDK1 CDK2
Dinaciclib 32 ± 2 2 ± 1 955 ± 246 41 ± 14
AZD5438 70 ± 13 4 ± 1 4,400 ± 3,200 26 ± 3
Alvocidib 28 ± 6 23 ± 3 1,600 ± 300 217 ± 1
CGP74514A 950 ± 50 224 ± 14 >20,000 715 ± 15
SU9516 234 ± 20 25 ± 5 >20,000 98 ± 1
Inhibitor binding was measured by isothermal titration calorimetry (ITC).
ITC titrations were carried out using phosphorylated monomeric CDK1
and CDK2, and CDK1-cyclin B (CDK1B) and CDK2-cyclin A (CDK2A)
complexes. Experiments were carried out with two biological replicates
(i.e., with n = 2), and values are quoted ± SD. Full results for both repli-
cates are shown in Table S2.
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greater than 20 mM (Figure S2B). In contrast, both Dinaciclib
and SU9516 retained their ability to bind tightly to cyclin-free
CDK2, returning Kd values of 41 and 98 nM, respectively. The
same pattern is seen for comparative binding of AZD5438
(Figure 2B), Alvocidib (Figure S2C), and CGP74514A (Fig-
ure S2D) to cyclin-free CDK1 and CDK2. Taken together the
ITC results reveal that ATP-competitive inhibitors show substan-
tially weaker binding to cyclin-free CDK1 than to CDK2 (Fig-
ure 2D). Moreover, a significantly reduced binding affinity is
observed for inhibitor binding to cyclin-free CDK1 in comparison
with the cyclin B bound complex (Table 1).
Using AZD5438 ITC isotherms we were able to calculate the
relative enthalpic and entropic contributions involved in inhibitor
binding to the different kinases in cyclin-free and cyclin-bound
states (Figure 2E). From this analysis, it appears that binding to
CDK1 and CDK2, in both cyclin-bound and cyclin-free forms,
is enthalpically favorable but entropically unfavorable under the
ITC conditions. However, binding of the inhibitor to either of
the cyclin-bound CDKs is less entropically unfavorable than
binding to the corresponding cyclin-free CDK, suggesting that
cyclin binding pre-organizes the CDK moiety so that inhibitor
binding carries a lower entropic penalty. Inhibitor binding to
cyclin-free CDK1 carries a similar entropic penalty to that asso-
ciated with binding to cyclin-free CDK2, so that the apparent
difference in affinity cannot simply be attributed to higher confor-
mational flexibility in apo cyclin-free CDK1.
We next employed surface plasmon resonance (SPR) as an
orthogonal technique to measure inhibitor binding to cyclin-
free CDK1 and CDK2 (Table 2). Glutathione-S-transferase
(GST) fusions of CDK1 and CDK2 were immobilized on a chip
coated with an anti-GST antibody and each inhibitor was flowed
over as the analyte. This study fully corroborated the results of
the ITC. AZD5438 (Figure 2C), Dinaciclib, SU9516, Alvocidib,
and CGP74514A (Figures S2A–S2D) all bound tightly to CDK2
with Kd values of 43, 78, 56, 650, and 312 nM, respectively. How-
ever, the inhibitor affinities (Kd) toward immobilized CDK1 were
all greater than 1 mM (Figures 2C and S2A–S2D).
Finally, we assessed the stability of cyclin-free forms of CDK1
and CDK2 using differential scanning calorimetry, and their
further stabilization upon inhibitor binding using differential scan-ning fluorimetry. cyclin-free CDK1 has a lower melting tempera-
ture than does CDK2 (48.9C ± 0.04C versus 51.52C ± 0.05C,
Figures S4A and S4B) and, as expected from the SPR and ITC
experiments, inhibitor binding stabilized CDK2 to thermal dena-
turation but had little effect on CDK1 (Table 2; Figures S4C and
S4D). In summary, our biophysical analyses demonstrate that
ATP-competitive inhibitors bind tightly to cyclin-bound CDK1
and CDK2 and to cyclin-free CDK2, but have much reduced
affinity for cyclin-free CDK1.
The Binding Mode of ATP-Competitive Inhibitors Is
Conserved between CDK1-Cyclin B and CDK2-Cyclin A
To elaborate themolecular interactions that mediate the different
binding affinities of inhibitors for cyclin-free and cyclin-bound
forms of CDK1 and CDK2, we undertook comprehensive co-
crystal structure determination for the inhibitor set. Although
some combinations of inhibitor and CDK did not yield well-dif-
fracting crystals, a total of 11 structures could be solved and
analyzed (Table S3).
Alvocidib, CGP74514a, and AZD5438 were co-crystallized
with CDK1-cyclin B-Cks2 (Table S3). Despite repeated co-crys-
tallization attempts we were unable to detect Dinaciclib and
SU9516 in the CDK1 active site. As expected, the chromone,
purine, and pyrimidine cores of Alvocidib (Figure 3A),
CGP74514a (Figure 3B), and AZD5438 (Figure 3C), respectively,
all form two hydrogen bonds with the CDK1 hinge through
hydrogen bonds to the main-chain amide of L83 and carbonyl
of E81 while being held in a hydrophobic sandwich between
L135 and A31. The cyclohexamine moiety of CGP74514a oc-
cupies the ribose binding pocket of CDK1, forming an additional
hydrogen bondwith themain-chain carbonyl ofQ132 (Figure 3B).
Alvocidib sits further back in the CDK1 active site than
CGP74514a (compare panels Figures 3A and 3B) and forms a
network of interactions through the piperidinol moiety with K33
and D146 within the phosphate binding pocket. The alkylated
imidazole group of AZD5438 is also accommodated within the
phosphate binding pocket and is stabilized through hydrophobic
interactions with V18 (Figure 3C). All three inhibitors form hydro-
phobic interactions with the CDK1 gatekeeper residue F80 that
forms the back corner of the active site cavity. The ethyl moiety
of CGP74514a stacks against the phenyl ring, while the pyrimi-
dine and chromone cores of AZD5438 and Alvocidib, respec-
tively, make ring edge-face interactions.
Toward the solvent-exposed selectivity surface on the C-ter-
minal CDK lobe, the phenylmethylsulfone group of AZD5438
forms a network of interactions (Figure 3C). A hydrogen bond
is made through the main-chain NH of D86 and hydrophobic in-
teractions with the side chain of I10 of the P loop act as a brace
between the two lobes. Both Alvocidib (Figure 3A) and
CGP74514a (Figure 3B) harbor a chlorophenyl group in this re-
gion; however, they adopt different poses. Alvocidib sits higher
in the pocket, which allows the chlorophenyl ring to rotate toward
the inhibitor core to take advantage of interactions with V18 and
I10 of the P loop. In contrast, the CGP74514a chlorophenyl
group is rotated away from the core, and, as it cannot be accom-
modated intra-molecularly, sits up against themain chain of M85
beyond the hinge region.
Superposition of the CDK1-cyclinB-Cks2 structures shows
that inhibitor binding drives the P loop to adopt a number ofCell Chemical Biology 26, 1–10, January 17, 2019 3
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Figure 2. Inhibitor Binding to CDK1 and CDK2
(A and B) Isothermal titration calorimetry (ITC) thermograms to assess AZD5438 binding to CDK1-cyclin B and CDK2-cyclin A (A) and cyclin-free CDK1 and CDK2
(B). For each sample, CDK1 and CDK2 were phosphorylated (on T161 or T160, respectively). AZD5438 shows reduced binding to cyclin-free CDK1 compared
with CDK1-cyclin (B).
(C) Surface plasmon resonance (SPR) studies to determine the binding of AZD5438 to CDK1 andCDK2. Unphosphorylated CDK1 and CDK2 asGST fusions were
immobilized on the SPR chip via anti-GST antibody coupling. Accompanying sets of ITC thermograms and SPR traces that evaluate Dinaciclib, SU9516,
Alvocidib, and CGP74514A binding are presented in Figure S2.
(D) Bar chart to compare the fold difference in binding affinity between cyclin-free CDK1 and CDK2 and their cyclin-associated forms. CDK1:CDK1-cyclin B and
CDK2:CDK2-cyclin A ratios are shown in black and gray, respectively. ITC experiments conducted in the presence of Cks2 are presented in Figure S3.
(E) ITC-derived energetic experimental data (DH, -TDS, and DG) for the binding of AZD5438 to CDK1 and CDK2 and their respective cognate cyclins.
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electron density and none of which have refined to particularly
high crystallographic temperature factors. A comparison of the
P loop in the Alvocidib- and AZD5438-bound complexes shows4 Cell Chemical Biology 26, 1–10, January 17, 2019a ‘‘tucked-in’’ Y15 accommodatedwithin the active site, reminis-
cent of the apo CDK1-cyclin B-Cks2 structure. However, in the
CGP74514a complex, Y15 does not fit and is forced to adopt a
‘‘popped-out’’ pose in which it coordinates to E163 on the
Table 2. Inhibitor Binding to CDK1 and CDK2
SPR Kd (nM) DTm (
C)
CDK1 CDK2 CDK1 CDK2
Dinaciclib 1,810 ± 150 78 ± 16 0.5 12.6
AZD5438 1,560 ± 220 43 ± 8.1 2.6 8.9
Alvocidib 1,080 ± 200 650 ± 230 0.9 7.3
CGP74514A 13,500 ± 1,000 312 ± 52 3.3 5.2
SU9516 5,840 ± 720 56 ± 26 1.5 11.7
Inhibitor binding was measured by surface plasmon resonance (SPR).
The DTm values were measured by differential scanning fluorimetry
(DSF). DTm represents the shift in Tm of monomeric CDK1 and CDK2 in
the absence and presence of each inhibitor. SPR andDSFmeasurements
were made with unphosphorylated and phosphorylated monomeric
CDKs, respectively. SPR experiments were carried out in duplicate,
and values are quoted ± SD.
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binding and contribute to its reduced potency toward CDK1
compared with Alvocidib and AZD5438.
A comparison of the binding modes of each of these three in-
hibitors to CDK1-cyclin B-Cks2 and to CDK2-cyclin A (Figure S5)
reveals that each inhibitor exploits very similar interaction net-
works to bind to both complexes, consistent with their compara-
ble binding affinities measured by ITC (Tables 1 and S2). A rela-
tive displacement of the C helix in the CDK1-cyclin B-Cks2
complexes compared with CDK2-cyclin A (Figure S5) is consis-
tent with that reported previously (Martin et al., 2017; Brown
et al., 2015), being far smaller than the displacement that accom-
panies cyclin binding and accommodated without affecting con-
tacts made to the inhibitors described here.
As the differences in the inhibitor affinities for cyclin-free CDK1
and CDK2 are more profound, we next sought to rationalize
these values by attempting to co-crystallize each inhibitor with
cyclin-free CDK1. These structures, taken together with struc-
tures for the matching CDK2-inhibitor co-complexes, would
allow a comparison of the molecular determinants that mediate
inhibitor binding to cyclin-free CDK1 and CDK2.
Structures of Dinaciclib and AZD5438 Bound to Cyclin-
free CDK1 Reveal Analogous Binding Modes to those
Observed when Bound to Cyclin-free CDK2
Crystals of the CDK1-Cks2 complex were grown in the presence
of each inhibitor. However, only two of the resolved structures
contained unambiguous density for bound inhibitor (Figure 4;
Table S3). CDK1-Cks2-Dinaciclib and CDK1-Cks2-AZD5438
crystallized in different lattices, which differ from the previously
published apo CDK1-Cks1 lattice (Brown et al., 2015).
Dinaciclib binds to cyclin-free CDK1 through the core pyrazolo
moiety, forming two hydrogen bonds with the main-chain NH
and carbonyl of L83 (Figure 4A). The ethyl group pendant to
the pyrazolo core is positioned up against F80, while the core
is sandwiched between the two lobes through hydrophobic in-
teractions with A31, V18, I10, V64, A145, and L135. The 2-hy-
droxyethyl group of the piperidine ring interacts with K33, which
stabilizes D146 and potentially forms an intramolecular hydrogen
bond with the pyrazolo core. Extending from the hinge toward
the solvent-exposed selectivity surface, the Dinaciclib pyridineoxide group stacks up against the main chain of I10 through
the face of the aromatic ring. Comparing the Dinaciclib-bound
CDK1-Cks2 structure with that of apo CDK1-Cks2 we observe
a slight, hydrophobicity-driven P loop movement toward the
inhibitor, which results in a reduction of the active site volume,
explaining the interactions we observe in the crystal structure.
However, a global superposition of CDK1-Cks2-Dinaciclib and
CDK2-Dinaciclib (PDB: 4KD1; Martin et al., 2013) (Figure 4B)
reveals little disparity between the two active site structures
(global superimposition root-mean-square deviation [RMSD] =
0.720 A˚) and does not identify marked differences in interactions
that would trivially explain the 20-fold difference in Dinaciclib po-
tency toward CDK2 and CDK1.
AZD5438 binds 170-fold more tightly to cyclin-free CDK2
than to CDK1 as determined by ITC measurements (Table 1).
Through its pyrimidine core this inhibitor makes two NH and
carbonyl L83 main-chain hydrogen bonds, while the aromatic
core is held in place by interactions with CDK1 F80, L135, and
A31 (Figure 4C). The phenylmethylsulfone moiety forms a poten-
tial hydrogen bondwith K89 through the sulfone, while the phenyl
ring sits up against I10 and is stabilized via an intramolecular
interaction with the isopropyl group of the alkylated imidazole.
These interactions are conserved in the cyclin-free CDK2-
AZD5438 complex (Table S3), and, again, the two structures su-
perimpose very well (global superposition RMSD = 1.043 A˚).
We investigated the possibility that crystal contacts might be
limiting the conformational responses of cyclin-free CDK1 and
CDK2 to inhibitor binding––and thereby concealing a trivial
explanation for the relatively low inhibitor binding affinity of cy-
clin-free CDK1––by comparing the available crystal forms of
CDK1 and CDK2 (Betzi et al., 2011; Bourne et al., 1996; Brown
et al., 2015; Jeffrey et al., 1995). Cyclin-free CDK2 crystallizes
in one major form with space group P212121. Although a signifi-
cant fraction of the CDK2 surface area in this crystal form partic-
ipates in crystal contacts, large conformational differences
involving the glycine lid, the C helix, and the activation segment
have been described for different CDK2-inhibitor complexes (for
example, see Figure S6A), suggesting that this crystal form is
capable of accommodating significantly different kinase confor-
mations. Thus, it is reasonable to conclude that the conformation
observed in our co-crystallization experiments with cyclin-free
CDK2 are not unduly constrained by lattice contacts. Taking
non-crystallographic symmetry into account, we have so far
observed cyclin-free CDK1 subunits in five distinct lattice
environments in two unrelated crystal forms. In each lattice envi-
ronment, the conformation of the major regulatory structural
elements is well preserved, and therefore unlikely to be driven
by specific local crystal contacts (Figure S6B). Thus, while we
cannot exclude an effect of the crystalline environment on the
structures described here, we think such an effect is unlikely to
dominate.
Comparing AZD5438 bound to CDK1-Cks2 (Figure 4C) and to
CDK1-cyclin B-Cks2 (Figure 3C, overlaid in Figure 4D), it is diffi-
cult to rationalize the 60-fold difference in affinity based purely
on a comparison of the identified interactions. However, a plau-
sible hypothesis is that cyclin binding reduces the overall entropy
of CDK1 and pre-arranges the CDK1 active site to make optimal
interactions with the ligand that results in greater affinity toward
small-molecule inhibitors. This hypothesis was tested using aCell Chemical Biology 26, 1–10, January 17, 2019 5
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Figure 3. Crystal Structures of CDK1-Cyclin
B-Cks2 Bound to Alvocidib, AZD5438, and
CGP74514A
(A–C) (A) Alvocidib, (B) CGP74514A, and (C)
AZD5438 all mimic the adenosine of ATP and bind to
the hinge region of CDK1 to form a number of in-
teractions within the binding pocket. The active site
of CDK1 is shown in white ribbons with key residues
depicted as cylinders. Inhibitors are shown in ball
and stick mode (carbon atoms yellow and chlorine
atoms green), with the supporting 2F0-Fc electron
densitymaps rendered inbluemeshcontoured at 1s
around the inhibitor. Potential hydrogen bonds are
shown in black dotted lines.
(D) Global superimposition of the three inhibitor
bound CDK1-cyclin B-Cks2 co-crystal structures to
show the various P loop conformations adopted to
accommodate inhibitor binding. CDK1 residues
11–17 in each inhibitor co-complex structure and the
bound inhibitors are colored as follows: Alvocidib
(pink), CGP74514A (limegreen), andAZD5438 (blue).
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Differences in the Stability and Flexibility of Cyclin-free
CDK1andCDK2Contribute to theObservedDifferences
in ATP-Competitive Inhibitor Binding
The relatively minor differences between the crystal structures of
cyclin-free CDK1 and CDK2 bound to AZD5438 and Dinaciclib
are hard to reconcile with the large differences in affinity
observed in our biophysical studies. One possible explanation
is that the differences in affinity arise from dynamic properties
of the different CDKs, and/or from structural differences be-
tween CDK1 and CDK2 complexes that are not expressed in
the crystalline state due to constraints imposed by lattice con-
tacts. If such properties underlie the biophysical results, then a
system-wide molecular dynamics (MD) energetic calculation
should be able to predict the affinities. Accordingly, we attemp-
ted affinity predictions using an MD-molecular mechanics en-
ergies combined with the Poisson-Boltzmann and surface area
continuum solvation (MM/PBSA) approach (Kumari et al., 2014).
The relative predicted affinities for Dinaciclib and AZD5438
binding to cyclin-free CDK1 and CDK2 were consistent with
our experimental findings, being substantially tighter for interac-
tions made with CDK2 than those made with CDK1 (Figure S7).
However, the ‘‘control’’ computational experiment of predicting
AZD5438 affinity for CDK1-cyclin B and CDK2-cyclin A did not
provide confidence in the significance of these calculations:
the calculations suggested that CDK1-cyclin B should bind
AZD5438 several orders of magnitude more tightly than does
CDK2-cyclin A (Figure S7). Indeed, even when attempting to
include a configurational entropy term in our analysis (Karplus
and Kushick, 1981; Hou et al., 2011), we were unable to recapit-
ulate the full set of experimental ITC observations. Therefore, we6 Cell Chemical Biology 26, 1–10, January 17, 2019conclude that MM/PBSA calculations at
the degree of sophistication applied here
are not able to capture the complex na-
ture of the comparative binding events
involved. It may be thatmore computation-ally rigorous methods (e.g., potential of mean force/umbrella
sampling; Steinbrecher and Labahn, 2010; Sun et al., 2015),
that better sample the conformational energy landscape, and/
or the energetic barriers between bound and unbound states,
would enable a quantitative predictive understanding.
Interaction Networks that Might Impact Inhibitor
Binding
Because our data suggested that plastic structural properties
might explain the observed range of binding affinities for
AZD5438, we surveyed the extent to which the different struc-
tures demonstrate proper assembly of two hydrophobic spines
that link the N- and C-terminal lobes of the kinase fold. These
two spines (the ‘‘regulatory’’ R-spine and the ‘‘catalytic’’ C-spine)
reconfigure dynamically to regulate the activity of several protein
kinases (Taylor andKornev, 2011) (Figure 5A). Our structural data
show that cyclin-bound CDK1 and CDK2 form the two
conserved hydrophobic spines (Figure 5B). However, in cyclin-
free CDK1 and CDK2 we observe misalignment of the R-spine,
due to displacement of L55 from the C helix, which may result
in reduced inter-lobe stability of the cyclin-free CDK forms.
In addition, cyclin-bound CDK1 and CDK2 form a series of in-
teractions between their respective N- and C-lobes through
atoms that derive from (1) the extended hinge region of the
C-lobe, (2) the base of the b sheet that comprises b1-5, (3) the
C helix (which is part of the N-lobe), and (4) the activation loop
(which forms part of the C-lobe). In total, these elements form
133 and 145 inter-lobe contacts (<4.0 A˚) for CDK1-cyclin B
and CDK2-cyclin A, respectively. This network of interactions
correlates with enhanced stability of the kinase fold and could,
in turn, enhance the binding of small-molecule inhibitors.
Although cyclin-free CDK1 and CDK2 form a broadly similar
set of inter-lobe interactions, they show a significantly smaller
A B
C D
Figure 4. Characterization of Inhibitor Bind-
ing to CDK1
(A) Dinaciclib binds to the ATP binding pocket of
CDK1-Cks2 through a series of hydrogen bonds
and hydrophobic interactions that are comparable
with those observed in the crystal structure of
CDK2-Dinaciclib (PDB: 4KD1).
(B) The binding poses of Dinaciclib in the inactive
CDK1-Cks2 and cyclin-free CDK2 ATP binding sites
are conserved and anchored by the pyrimidine core.
(C) AZD5438 bound to cyclin-free CDK1-Cks2
through a series of hydrogen bonds and hydro-
phobic interactions. The active sites of CDK1 and
CDK2 are shown in white and blue ribbons,
respectively, with key residues and inhibitors de-
picted in cylinder or yellow ball and stick styles,
respectively. The 2F0-Fc electron density map is
drawn as a blue mesh contoured at 1s around the
inhibitor. Potential hydrogen bonds are shown as
black dotted lines.
(D) Comparison of the co-crystal structures of
AZD5438 bound to cyclin-free and cyclin B bound
active CDK1 to compare the key kinase motifs,
namely the P loop, C helix, and activation segment.
CDK1-cyclin B is drawn as a lime green ribbon and
magenta surface.
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loop. Notably, however, residues T14 and Y15 from the P loop of
cyclin-free CDK2 pack against the HRDmotif of the CDK2 activa-
tion loop (Figure 5B) to forman interaction network that is not seen
incyclin-freeCDK1. Itmaybe that conformational stabilization that
derives from thesecontacts contributes to the tighter binding of in-
hibitors to cyclin-free CDK2 than to cyclin-free CDK1. Overall, the
number of inter-lobe contacts in cyclin-free CDK1 (104 contacts
shorter than 4.0 A˚) is the smallest of any state evaluated here,
and compares with a count of 141 for cyclin-free CDK2.
Whether or not the specific contacts enumerated here
contribute directly to enhanced inhibitor binding for CDK2 versus
CDK1, they provide a structural basis for the suggestion that the
conformational energy landscape of cyclin-free CDK1 differs
from those of CDK2, CDK2-cyclin A, and CDK1-cyclin B in a
way that might explain CDK1’s relatively low propensity to bind
small-molecule ligands.
DISCUSSION
The development of CDK inhibitors for clinical use is compli-
cated by the challenge of achieving the best possible spectrum
of activity against different CDK family members. In particular, a
broad selectivity is thought to contribute to the dose-limiting
toxicity that has led to the closure of a number of clinical pro-
grams (Asghar et al., 2015; Mariaule and Belmont, 2014; Whit-
taker et al., 2017). The recent successful CDK4/6 programs of
IBRANCE, KISQALI, and VERZENIO are selective over CDK1
(Vijayaraghavan et al., 2017; Whittaker et al., 2017), and a com-
parison of the CDK4 and CDK1 active sites shows the potential
for obtaining selectivity by exploiting sequence differences. In
contrast, discriminating against CDK1 for a CDK2 drug discov-ery program appears more challenging because of the high
degree of active site sequence identity between the two CDKs,
and the similarity of their active site structures when bound to
their cognate activating cyclins.
Our results suggest that targeting cyclin-free CDK2 could yield
a window of selectivity over CDK1 that has not been accessible
to drug discovery campaigns that target CDK2-cyclin com-
plexes. The feasibility of generating an inhibitor that selectively
binds to cyclin-free CDK2 has been suggested by results gener-
ated elsewhere (Alexander et al., 2015; Deng et al., 2014). These
programs have developed compounds that bind tightly to cyclin-
free CDK2 by exploiting an allosteric pocket and, in one case
(Alexander et al., 2015), by altering the conformation of the
DFG motif. Elsewhere, compounds that bind relatively weakly
to monomeric CDK2 have revealed further space that can be
exploited by inhibitors that bind outside the conventional ATP
binding site (Betzi et al., 2011). However, no such inhibitor has
yet been reported to provide potent inhibition of CDK2 kinase
activity (compounds reported to be inactive at 10 mM).
Crystallographic structures reveal only minor differences in in-
teractions between ATP-competitive inhibitors and cyclin-free
and cyclin-bound forms of CDK1 and CDK2. From these differ-
ences, it is hard to explain the 100-fold difference in affinities of
the inhibitors for the different protein targets. Accordingly, we
have investigated whether the differences in affinity might be ex-
plained by the flexibility, plasticity, and entropic properties that
can be interrogated in MD simulations of the different apo- and
ligand-bound CDKs. These studies suggest that MD/MM-PBSA
cannot provide a comprehensive predictive model for the ligand
binding properties of the differentCDKs indifferent states of cyclin
binding. A qualitative indication of differing conformational energy
landscapes for these targets was, however, indicated by anCell Chemical Biology 26, 1–10, January 17, 2019 7
A B
Figure 5. Plasticity of CDK Fold Regulated through the Hydrophobic Spine
(A) Inter-lobal stability of CDK fold, N-lobe (pink), C-lobe (orange), with hydrophobic regulatory spines of R-spine and C-spine shown in blue and red, respectively.
Inset shows the C-spine and R-spine of CDK1 (red and blue) and CDK1-cyclinB (pink and cyan).
(B) Cyclin-free CDK2 stability through interactions of the P loop in the N-lobe (purple) and activation loop of the C-lobe (orange).
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2011) and an enumeration of their inter-lobe contacts. These ana-
lyses showed that contacts between the P loop and the activation
segment of cyclin-free CDK2might predispose it to inhibitor bind-
ing relative to cyclin-free CDK1, and that cyclin binding completes
the formation of the regulatory spines of both kinases in away that
may contribute to the tighter binding of inhibitors to CDK-cyclin
complexes. Overall, we conclude that the enhanced propensities
of cyclin-freeCDK2, cyclin-boundCDK2, and cyclin-boundCDK1
to bind to ligands, relative to that of cyclin-freeCDK1, derives from
a complex interplay between dynamic and plastic properties of
cyclin-free CDK1.
A characteristic of protein kinases is their ability to signal the
presence of ligands boundat the active site throughout the kinase
domain to affect downstream kinase-dependent pathways (Kor-
nev and Taylor, 2015). The ability to remodel the CDK active site
underpins a variety of mechanisms that regulate CDK activity by
phosphorylation (Morgan, 2007; Welburn et al., 2007) or binding
to INK and CIP/KIP inhibitory proteins (Morgan, 2007; Pavletich,
1999). CDK4 retains an inactive conformation even when cyclin-
boundandphosphorylatedon theactivationsegment, suggesting
that binding of the protein substrate is required in order for
the Michaelis complex to form (Day et al., 2009). Taken together,
these examples illustrate how sequence flexibility local to the
active site and structural re-organization of the kinase domain
are significant elements of CDK regulation. We hypothesize
that, in addition to contributing to the unique activities of CDK1
as a cell-cycle regulator, the particular dynamic and plastic prop-
erties of CDK1 might also be exploited to successfully differen-
tiate CDK1 from other CDKs in future cancer therapeutic design.
SIGNIFICANCE
This paper explores the adaptive nature of CDK1 and CDK1-
cyclin B relative to CDK2 and CDK2-cyclin A by probing with8 Cell Chemical Biology 26, 1–10, January 17, 2019a collection of ATP-competitive inhibitors. These inhibitors
onlymodestly discriminate between cyclin-associated forms
of CDK1 and CDK2, but bind much less tightly to cyclin-free
CDK1 than to cyclin-free CDK2. These results hint at a
different conformational energy landscape of cyclin-free
CDK1comparedwithcyclin-freeCDK2,which isnotapparent
in cyclin-associated forms. This difference may underlie the
essential cell-cycle role of CDK1, which can bind a sufficient
set of cyclins to drive all phases of the cell cycle (Santamaria
et al., 2007), and can phosphorylate suboptimal model sub-
strates in a reconstituted system (Brown et al., 2015).
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METHOD DETAILS
Protein Expression and Purification
Human CDK1 and CDK2, and Cks2, and human cyclin A and B sequences were expressed, purified and assembled as required into
complexes as described (Brown et al., 2015). Full-length human CDK1 was expressed in insect cells either untagged (from pVL1393)
or as a 3C-protease cleavable GST fusion. To prepare the GST fusion, the CDK1 sequence was initially cloned into pGEX6P-1 as a
Sma1-EcoR1 fragment. A cassette to express the fusion protein was extracted from recombinant pGEX6P-1 and cloned into the
transfer vector pVL1393 and verified by DNA sequencing. Recombinant virus was generated using Sf9 cells co-transfected with
pVL1393GST-CDK1 and FlashBacGold DNA (Oxford Expression Technologies) mixed with transfection reagent (GeneJuice, Nova-
gen) and grown in SF900 II SFMmedia (LifeTechnologies). CDK1 expression was subsequently optimized by screening different virus
stock:cell ratios. To purify GST-CDK1, cell pellets were resuspended in mTBS buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM dithio-
threitol (DTT), pH7.5) supplemented with 200 mM RNAase A, 200 mMDNAaseI and 200 mMMgCl2, lysed by sonication then clarified
by centrifugation (60,0003 g, 1 h). GST-CDK1was subsequently purified by sequential affinity chromatography (glutathione-sephar-
ose 4B, GE Healthcare), GST-3C cleavage (1:50 w/w at +4 C overnight) and a final size-exclusion chromatography (SEC) step
(Superdex 75 26/60 column, GEHealthcare equilibrated in mTBS). Preparation of human cyclin B1 residues 165–433 carrying the
C167S/C238S/C350S mutations, human cyclin A2 and bovine cyclin A2 (residues 172-430 (differing in 8 residues from human)
used in only ITC experiments because human cyclin A is unstable in the absence of CDK2) were expressed in recombinant E. coli
cells and purified as described in Brown et al., 2015. Human Cks1 and Cks2 were expressed as His6-or GST-tagged proteins,
respectively, and purified by sequential affinity (Ni-NTA or glutathione-sepharose 4B), 3C cleavage (in the case of the GST fusion)
and SEC steps. To prepare the CDK1–Cks1 complex, purified His-tagged Cks1 was immobilized on Ni-NTA and used to capture
untagged CDK1 from insect cell lysate. The complex was eluted with imidazole and further purified by SEC on a HR26/60 SD75 col-
umn (GE Healthcare) equilibrated in HBS (10 mM HEPES pH 7.5/150 mM NaCl/0.01% monothioglycerol (MTG)/0.01% sodium
azide). To prepare the ternary CDK1–cyclin B-Cks2 complex, components were individually purified and then mixed in a molar ratio
of 1:1.5:2, CDK1:cyclin B:Cks2. The final step to assemble the complex was carried out on a Superdex 75 HR26/60 size-exclusion
column equilibrated in a modified Tris-buffered saline containing 1.0 M NaCl, 50 mM Tris-HCl, pH 8.0, 1 mMDTT. Fractions contain-
ing the desired complexes were pooled, and both were concentrated to circa 10–12 mg ml1 by ultrafiltration. Both the CDK1–Cks1
and CDK1–cyclin B–Cks2 complexes can be successfully crystallized from frozen samples. Proteins were concentrated to circa
10–12 mg ml1 and then fast frozen in aliquots in liquid nitrogen before storage at 80C. CDK2 suitable for crystallography was
prepared as described in (Martin et al., 2012). Human CDK2 (encompassing full length residues 1-298) was cloned into a pGEX6P1
vector (GE Healthcare) and then transformed and expressed in BL21(DE3)STAR E. coli, then grown at 37C until an optical density of
0.4-0.6 before decreasing the temperature to 18Cwith 0.2 mM IPTG (Isopropyl b-D-1-thiogalactopyranoside; Sigma) induction and
incubation for a further 16-20 hours. Cells were then harvested by centrifugation (4,000 xg, 30 mins, 4C) before resuspension in
50 mM HEPES, 150 mM NaCl, 2 mM DTT, pH 7.4. Cells suspensions were then supplemented with 2 ug/mL DNase I, 10 ug/mL
RNase A, 25 ug/mL lysozyme and 5 mMMgCl2 for to aid lysis. Cell suspensions were then lysed via sonication (5 mins total, pulsed
20s on, 40s off) and lysate clarified via centrifugation (40, 000 xg, 60 mins, 4C). Recovered lysate was then bound to glutathionee2 Cell Chemical Biology 26, 1–10.e1–e5, January 17, 2019
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elution in 50 mM HEPES, 150 mM NaCl, 2 mM DTT, 10 mM reduced glutathione, pH 7.4. Eluted GST-CDK2 proteins were then
cleaved overnight (16 hours) at 4Cusing 1:100mass:mass of 3C protease:GST-CDK2. Cleaved product then underwent gel filtration
(s75 preparative grade Superdex HiLoad (GE Healthcare)) with peak, GST-free fractions then buffer exchanged, using a HiTrap
desalting column (GE Healthcare), into 100 mM 4:1 K2:Na phosphate, 2 mM DTT, buffer and concentrated to 10 mg mL
-1.
Crystallisation and Structure Determination
Crystals of CDK1–cyclin B-Cks2 bound to -Alvocidib, -CGP74514a and -AZD5438 were grown and cryo-protected as described
(Brown et al., 2015). Briefly, crystals were grown by adding each inhibitor in two-fold molar excess (which was also a >10-fold higher
concentration than the inhibitor IC50) to a low concentration solution of CDK1–cyclin B-Cks2 and then concentrating the sample to
10–12 mg ml-1. Monomeric CDK1-Cks2-Dinaciclib and -AZD5438 complexes were prepared by concentrating CDK1-Cks2 and in-
hibitor stock solutions as described above. Subsequent crystallisation and cryo-protection was as described for the apo-CDK1-Cks1
complex (Brown et al., 2015). CDK2-cyclin A- Alvocidib, -CGP74514a, SU9516 and -AZD5438 crystals were grown and harvested as
described (Coxon et al., 2017). Monomeric CDK2 crystals grown as described (Martin et al., 2012), were soaked with both AZD5438
and CGP74514A at 1mM, 10% DMSO for 2 days. The crystals were then harvested into a cryoprotectant of 30% ethylene glycol
diluted from a 100% stock with precipitant solution. X-ray diffraction data were recorded at Diamond Light Source, Oxford, UK.
The programs within the CCP4i2 software package (Potterton et al., 2018; Winn et al., 2011) were employed throughout the structure
determination process. Data were processed using DIALS (Waterman et al., 2013) and XDS (Kabsch, 2010) within Xia2, while
PHASER (McCoy et al., 2007) was employed for phasing and REFMAC (Murshudov et al., 2011) used during refinement. Model build-
ing was performed using COOT (Emsley et al., 2010) with AceDRG used for generation of inhibitor descriptions (Long et al., 2017).
Figures were prepared using CCP4MG (McNicholas et al., 2011).
Isothermal Titration Calorimetry
Individual protein samples were exchanged into ITC buffer (40 mM HEPES, 500 mM NaCl, 0.25 mM TCEP, pH 8.0) at 4C using a
Hitrap desalting column (GE Healthcare Life Sciences, Chicago, IL, USA) (i.e. CDK1 and cyclin B were not combined to form a com-
plex prior to buffer exchange). Protein concentration was then determined at A280 nm using a Nanodrop 2000 (Thermoscientific, Wal-
tham, MA, USA) and sequence derived extinction coefficients (http://web.expasy.org/protparam/). Proteins and compounds were
degassed at 30C directly before analysis. Compounds at 100 mM prepared in ITC buffer (40 mM HEPES, 500 mM NaCl,
0.25 mM TCEP, pH 8.0) and to a final DMSO concentration of 1% were titrated into 200 mL protein solutions prepared at 10 mM,
1% DMSO in the cell. All experiments used phosphorylated forms of CDK1 and CDK2 (on T161 or T160 respectively). For experi-
ments carried out in the absence of cyclin, proteins were prepared on ice to a final concentration of 10 mM in ITC buffer and supple-
mented with 1% DMSO. Regarding CDK-cyclin or CDK-Cks2 titrations, complexes were prepared from individual buffer exchanged
components at 1:1 equimolar concentrations (10 mMeach, accounting for 1:1 stoichiometry) and incubated on ice for 30mins prior to
degassing and analysis. All ITC measurements were carried out at 30C on a Microcal ITC 200 (Malvern Instruments Ltd, Malvern,
UK). Titrations began with an initial 0.5 mL injection followed by 19 x 2 mL injections of compound, with 120 s spacing between each
injection, and stirred at 1000 rpm throughout the experiment. Data were then analysed using Origin 7.0 (OriginLab Corp., Burlington,
NC, USA) and fit with the one-set-of-sites model to calculate the dissociation constant and the error of the fit. Data are representative
of at least two separate experiments from two separate biological preparations of protein.
Differential Scanning Calorimetry
The stability of the monomeric phosphorylated CDK1 and CDK2 were assessed by differential scanning calorimetry (DSC) using the
Microcal VP-DSC (Malvern Instruments Ltd, Malvern, UK). Proteins were desalted in DSC buffer (50 mM HEPES, 150 mM NaCl,
0.25 mM TCEP, pH 7.4) at 4C using a Hitrap desalting column (GE Healthcare Life Sciences, Chicago, IL, USA). Protein concentra-
tion was then determined at A280 nm using a Nanodrop 2000 (Thermoscientific, Waltham, MA, USA) and sequence derived extinction
coefficients (http://web.expasy.org/protparam/). Prior to analysis, buffer equilibration was carried out overnight to obtain a stable
baseline. Six overnight buffer equilibration scans were carried out using a starting temperature of 25C, and an end temperature
of 90C at a rate of 90C/hour. The pre-scan thermostat was set to 15 and the post-scan thermostat set to 0. Using the same tem-
perature start- and end-points and rate, protein stability testingwas carried out using 700 mL of CDK1 or CDK2 at 23 mM.Buffer-buffer
equilibration runs were subtracted from protein-buffer scans, normalised for protein concentration and fit to a non-two state model
usingOrigin 7.0 (OriginLab Corp., Burlington, NC, USA) software to calculate themelting temperature (Tm) and corresponding error of
the fit. Experiments were conducted in singletons.
Differential Scanning Fluorimetry
The stability of the CDK1 and CDK2 inhibitor complexes were assessed by differential scanning fluorimetry (DSF) using a ViiA7 Real-
Time PCR system (Applied Biosystems). Purified CDK1 (4 mM) and CDK2 (6 uM) in their respective gel filtration buffers were assayed
in the presence of 10 mM inhibitor in 8% DMSO, in triplicate, in a 384-well plate. SyPRO Orange (x10) (Invitrogen) was used as the
fluorescent probe, and fluorescence was measured using the ROX reporter channel (excitation l=470 nm, emission l = 586nm).
Complex stability was assessed by increasing the temperature from 25 to 95C through 1C increments. The resulting data was
plotted and the inflection point (Tm) calculated using the Boltzmann equation in Applied Biosystems software.Cell Chemical Biology 26, 1–10.e1–e5, January 17, 2019 e3
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Evaluation of the inhibitors were carried out in ADP-GloTM format essentially as described previously (Brown et al., 2015). Briefly,
the 5 inhibitors in the study were titrated against phosphorylated CDK2–cyclin A and CDK1–cyclin B, with reaction initiated through
addition of ATP and substrate peptide HHASPRK (Enzo Scientific). ATP to ADP conversion was assessed using the ADP-Glo assay
(Promega) essentially as described by the manufacturers. In brief, reactions were carried out at room temperature in 40 mM Tris-HCl
pH 7.5, containing 20 mM MgCl2, 0.1 mg ml
-1 BSA, using 4 nM CDK1-cyclinB or 1.5 nM CDK2–cyclin A incubated with inhibitors
through a 12 points (0-6 mM) titration. Reactions were initiated by the addition of 20 mM ATP and 20 mM peptide. All activity assays
were performed in triplicate in white low volume 384-well plates using a PheraStar plate reader (BMG). IC50 values were obtained by
fitting the data to the equation Y=1/(1+10^((LogIC50-[inhibitor])*N)) using PRISM (GraphPad).
Molecular Dynamics Simulations
The complexes of CDK1-AZD5438 and -Dinaciclib was derived by removing Cks2 and all water and solventmolecules. Complexes of
CDK2-AZD5438 and CDK2-Dinaciclib (PDB: 4KD1), and complexes for CDK1-Cyclin B-AZD5438 and CDK2-Cyclin A-AZD5438
were prepared by removal of water and any additional solvent molecules. Parameters for phosphothreonine in complexes CDK2-
AZD5438 and CDK2-CyclinA-AZD5438 were derived from Homeyer et al.’s published set for AMBER (Homeyer et al., 2006). Ligand
topologies were prepared in Antechamber (Wang et al., 2006) from AmberTools16 and converted to GROMACS format using
ACPYPE (Sousa da Silva and Vranken, 2012). Simulations were performed in GROMACS 5.1.4 (Van Der Spoel et al., 2005) using
1 NVIDIA GeForce GTX 1008 GPU and 10 Intel Xenon E5-2630 CPU threads. Each system was parameterised in the AMBER99SB
(Hornak et al., 2006) forcefield and solvated in a cubic box with a 10 A˚ shell of TIP3P water. The systems were then neutralised using
NaCl to a final concentration of 0.5 M to correspond to the biophysical experimental conditions, followed by steepest descent energy
minimisation to a target Fmax of < 1000 kJ mol-1 nm-1, achieved in under 2000 steps in all cases. Each system was subject to 200 ps
equilibration at 300 K in the NVT ensemble using 2 fs steps. Equilibration was continued in the NPT ensemble for 500 ps using 2 fs
steps. Atom positions were restrained during equilibration and released for production MD. Three production MD runs were per-
formed using the equilibrated system as a starting point for a total of 10 ns in 2 fs steps utilising Nose-Hoover temperature coupling
with a Parinello-Rahman pressure coupling. Energies and co-ordinates were written every 5000 steps (10 ps) for analysis. Conver-
gence was determined by tracking the LJ and coulombic energies throughout the simulation, as well as the RMSD of both the protein
alpha-carbons and the drug itself and the best converged run(s) were utilised for MM/PBSA calculation.
Surface Plasmon Resonance
SPR ligand interactions assays were performed on a Biacore S200 (GE Healthcare Life Sciences) at 20C using multi-cycle settings.
GST-tagged unphosphorylated CDK1 and CDK2 were immobilised onto the surface of a CM5 chip pre-immobilised with anti-GST
antibody, provided as part of the GST-capture kit (GE Healthcare Life Sciences, catalogue number BR100223) following the GST
immobilisation kit instructions. As a control, recombinant GST was immobilised onto the designated control flow cell. GST, GST-
CDK1 and GST-CDK2 were then prepared at concentrations of 20 mg/mL, 50 mg/mL and 50 mg/mL respectively in DMSO-free
SPR running buffer (20 mM HEPES, 150 mM NaCl, 0.01% Tween-20, pH 7.4) and injected onto separate flow cells eliciting
response units (RUs) of 620, 1900 and 2244 RUs, respectively. Preceding injection of each compound, three cycles of buffer injec-
tions were carried out over all surfaces (30 mL/min for 60 s with 360 s dissociation). Compounds were then injected over all surfaces
(from low to high concentration) for 60 s at 30 mL/min before being allowed to dissociate for 360 s to record dose-responses. 11 (GST-
CDK2) or 12 (GST-CDK1) concentrations (0 nM, 0.05 nM, 0.19 nM, 0.76 nM, 3.05 nM, 12.21 nM, 48.83 nM, 195.31 nM, 781.25 nM,
3125 nMand 12500 nM,with an extra concentration of 50000 nM for GST-CDK1) of compoundwere prepared at 1%DMSO in 20mM
HEPES, 150 mM NaCl, 0.01% Tween-20, pH 7.4 in series across all flow cells using solvent correction. The experiment was con-
ducted in SPR running buffer (20 mM HEPES, 150 mM NaCl, 0.01% Tween-20, 1% DMSO, pH 7.4) and used an 8-point DMSO
solvent correction (preparation of DMSO in DMSO-free SPR buffer to final concentrations of: 0.2%, 0.4%, 0.6%, 0.8% 1%, 1.2%,
1.4%, 1.6%) to account for any bulk flow interactions. Similarly, all responses were subtracted from the GST immobilised reference
flow cell. Responses were analysed using Biacore s200 Evaluation Software (GE Healthcare Life Sciences, Chicago, IL, USA) using
affinity fit to determine the Kd and standard error (SE) of the fit. Data are representative of two technical replicates.
MM/PBSA Calculations
The g_mmpbsa tool (Kumari et al., 2014) was utilised to calculate the binding energy between protein and ligand via APBS
v. 1.4.1(Baker et al., 2001) using a solute dielectric constant of 1 and a solvent dielectric constant of 80. The final 4 ns of converged
simulation time was used for binding energy determination. Parameters such as temperature and ion concentration were matched to
the simulation parameters. Output energies were converted from kJ mol-1 to kcal mol-1, and log10 fold-changes calculated using
DDG/1.4 kcal mol-1.
Entropy Calculations
The configurational entropy of each systemwas calculated as the quasiharmonic approximation of the entropy(Karplus and Kushick,
1981), as calculated in GROMACS based on the method of Karplus and Kushik. A covariance matrix was generated using gmx covar
for each production MD run, based on the alpha-carbons of the protein component of each system, which was subsequently used to
calculate the entropy using gmx anaeig with a specified temperature of 300K. The entropy for each complex was then averaged ande4 Cell Chemical Biology 26, 1–10.e1–e5, January 17, 2019
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DATA AND SOFTWARE AVAILABILITY
All crystallographic results were deposited to and are accessible from the Protein Data Bank (PDB) https://www.rcsb.org/.
PDB accession codes for all structures derived from this study are as follows:
CDK1/cyclin B/Cks2 + AZD5438 (PDB: 6GU3), CDK1/cyclin B/Cks2 + Alvocidib (PDB: 6GU2), CDK1/cyclin B/Cks2 + CGP74514A
(PDB: 6GU4), CDK1/Cks2 + Dinaciclib (PDB: 6GU6), CDK1/Cks2 + AZD5438 (PDB: 6GU7), CDK2/cyclin A + Alvocidib (PDB: 6GUB),
CDK2/cyclin A + SU9516 (PDB: 6GUC), CDK2/cyclin A + AZD5438 (PDB: 6GUE), CDK2/cyclin A +CGP74514A (PDB: 6GUF), CDK2 +
AZD5438 (PDB: 6GUH), CDK2 + CGP74514A (PDB: 6GUK).
PDB accession codes for structures used within, but not derived from, this study:
CDK1/Cks1 (PDB: 4YC6), CDK2/cyclin A (PDB: 1FIN), CDK2/Cks1 (PDB: 1BUH), CDK2 (PDB: 1HCK), CDK2 + Dinaciclib (PDB:
4KD1), CDK2 + JWS648 + ANS (PDB: 3PXZ).Cell Chemical Biology 26, 1–10.e1–e5, January 17, 2019 e5
